Clinical trial NCT05184127: Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19
Official title: Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: COVID-19
Keywords: COVID-19
siRNA
SARS-CoV-2
Lead sponsor: National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Sponsor class: OTHER
Collaborators: name: St. Petersburg Research Institute of Vaccines and Sera
First posted: 2022-01-11
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19® via 14 days of treatment of participants with symptomatic moderate COVID-19.

The purpose of this study is to evaluate the efficacy, safety and daily dose of MIR 19 ® for the treatment of the hospitalized patients with infection caused by SARS-CoV-2 (COVID-19) who did not require treatment in the intensive care unit.

Based on preclinical data studying antiviral effect of MIR 19® in vitro and in vivo (Khaitov M.R. et all 2021), the investigators hypothesized that SARS-CoV-2 inhibition with MIR 19® could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.

Detailed description: This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19 ® in male and female volunteers with symptomatic moderate COVID-19 who did not require treatment in the intensive care unit.

The MIR 19® is a complex of siRNA, targeting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and peptide dendrimer KK-46.

This study involved 3 cohorts who received:

1. standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
2. 3.7 mg of the MIR 19 ® via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
3. 11.1 mg of the MIR 19 ® via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.

All subjects will undergo scheduled safety and efficacy assessments while in the clinical unit and as outpatients to the end of the follow-up period.

Eligibility criteria: Inclusion Criteria:

1. Men or non-pregnant female aged 18 to 65 years hospitalized with moderate COVID-19 infection: body temperature \> 37.5 °C; respiratory rate \> 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (CT) changes (CT1- CT2); pulse oximetry levels SpO2\< 95%.
2. Able to give informed consent and attend all study visits
3. Positive PCR-test for COVID-19 ≤72 hours prior to randomization
4. The patient's ability to inhale the experimental drug
5. Participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month

Key Exclusion Criteria:

1. Fever \> 38.5°C.
2. Cough severity is less than 1 point on a 4-point scale.
3. Respiratory rate \> is more than 30 / min
4. SpO2 ≤ 93%.
5. Decreased level of consciousness, agitation.
6. Unstable hemodynamics (systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg).
7. The need to require mechanical ventilation beyond the screening/ randomization.
8. Long-term systemic corticosteroid exposure.
9. Autoimmune or inflammatory diseases (systemic / localized).
10. Positive blood tests for HIV, hepatitis B and С, syphilis.
11. Pregnancy and breast-feeding
12. Previous adverse reactions to the active substance and/or excipients included in the drug.
13. Any use of anti-viral medications or immunomodulatory agents up to 7 days before participating in the study
14. Chronic diseases of the cardiovascular system
15. Type 1 diabetes
16. The following laboratory parameters are excluded:

    Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and direct bilirubin \>4 x upper limit of normal (ULN);
17. Treatment with any medicine that have a pronounced effects on the blood coagulation system (expect for COVID-19 treatment), including combined oral contraceptives.
18. Treatment with any medicine that can affect cardiac conduction
19. Participation in other investigational drug or device clinical trials within 90 days prior to screening.
20. History of alcohol, drug or chemical abuse.
21. Mental illness.
22. Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) up to 14 days before participating in the study, vaccination against SARS-CoV-2 , the need for extracorporeal membrane oxygenation.
23. Any conditions that, according to the researcher's, may be a contraindication to the participation in the study.

Primary outcomes:
measure: Relief of fever
timeFrame: Within 14 days
measure: Respiratory rate
timeFrame: Within 14 days
measure: Oxygen saturation
timeFrame: Within 14 days
measure: Severity of cough
timeFrame: Within 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: NRC Institute of Immunology FMBA
Study officials:
References: